AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03157388
Drug: Combined Vancomycin and Gentamycin and Meropenem
RxNorm normalized name: meropenem and vaborbactam
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice.
Trial: NCT03187678
Drug: i.v. selexipag
DrugBank: Selexipag (DB11362)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
Trial: NCT03187678
Drug: oral selexipag (Uptravi)
RxNorm normalized name: selexipag Injection [Uptravi]
DrugBank: Selexipag (DB11362)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
Trial: NCT00125307
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02303678
Drug: D2C7-IT
RxNorm normalized name: D2C7-IT
DrugBank: D2C7 immunotoxin (DB17540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
Trial: NCT03681509
Drug: Pramipexole
RxNorm normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramipexole
Trial: NCT00759928
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg once daily by mouth
Trial: NCT00759928
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg twice daily by mouth
Trial: NCT00821028
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm\^3
Trial: NCT00074204
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT00074204
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT00074204
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT02700568
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
Trial: NCT02247960
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00627302
Drug: PEG-400
RxNorm normalized name: PEG-400
DrugBank: Polyethylene glycol 400 (DB11077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
Trial: NCT00627302
Drug: Systane
RxNorm normalized name: Systane
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
Trial: NCT00484432
Drug: NGR-hTNF
RxNorm normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs
Trial: NCT01205711
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01205711
Drug: zibotentan
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03000283
Drug: Conivaptan
RxNorm normalized name: Conivaptan
DrugBank: Conivaptan (DB00872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line.
Trial: NCT03714815
Drug: macitentan 10 mg
RxNorm normalized name: macitentan 10 MG
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: macitentan 10 mg, film-coated tablet, oral use
Trial: NCT02049268
Drug: Nicotine + Alcohol
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
Trial: NCT00754923
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
Trial: NCT03824483
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zanubrutinib (160mg by mouth BID)
Trial: NCT03824483
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: obinutuzumab (1000mg IVPB on Days 1\*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). \* On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC \>25,000 cells/ul or baseline lymph nodes \>5 cm diameter).
Trial: NCT03824483
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
Trial: NCT02520505
Drug: Supraovulation clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
Trial: NCT04115059
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral, daily, dosing per protocol, once a day for cycle
Trial: NCT01509300
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/M2 once daily IV on days -8 to -4
Trial: NCT02022930
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00368550
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
Trial: NCT01509300
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: begin on 0
Trial: NCT01509300
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: begin on 0
Trial: NCT01509300
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375mg/m2 on day +21
Trial: NCT04335578
Drug: Zampilimab
RxNorm normalized name: Zampilimab
DrugBank: Zampilimab (DB16381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive zampilimab (UCB7858) at pre-specified time-points.
Trial: NCT01059084
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg tid
Trial: NCT03613844
Drug: DHA
RxNorm normalized name: DHA
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DHA supplementation
Trial: NCT02206048
Drug: Proflavine
RxNorm normalized name: proflavine
DrugBank: Proflavine (DB01123)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
Trial: NCT00670241
Drug: calcipotriol and betamethasone (LEO 80185 gel)
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once daily application
Trial: NCT00670241
Drug: Tacalcitol ointment
RxNorm normalized name: tacalcitol
DrugBank: Tacalcitol (DB13689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily application
Trial: NCT03281577
Drug: TAK-954
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-954 IV infusion.
Trial: NCT01429415
Drug: Magnesium Sulfate Sandoz
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
Trial: NCT01429415
Drug: Sodium Chloride , USP PPC
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
Trial: NCT04056611
Drug: JNJ-53718678 250 mg
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-53718678 250 mg will be administered orally.
Trial: NCT04056611
Drug: JNJ-53718678 125 mg
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-53718678 125 mg will be administered orally.
Trial: NCT02802969
Drug: 18F FAZA
RxNorm normalized name: Fludeoxyglucose (18F)
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FAZA PET/CT, in order to target the hypoxic zones
Trial: NCT01541280
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of \>15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of \>1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
Trial: NCT00813332
Drug: Endostar(rh recombinant endostatin) plus Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Trial: NCT00813332
Drug: Placebo plus Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo plus Docetaxel
Trial: NCT03755791
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Supplied as 20-mg tablets; administered orally daily at 40 mg
Trial: NCT03755791
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Supplied as 60-mg tablets; administered orally once daily at 60 mg
Trial: NCT02972840
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally (PO)
Trial: NCT02972840
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously (IV)
Trial: NCT02972840
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously (IV)
Trial: NCT03869190
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For the control, + EV, + Nira, + Tira, and + SG arms, + RO7122290, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.
Trial: NCT03869190
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
Trial: NCT03755791
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplied as 200-mg tablets; administered orally twice daily at 400 mg
Trial: NCT03755791
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Supplied as 1200 mg/20 mL (60 mg/mL) in sing-dose vials; administered as an IV infusion once every 3 weeks (q3w).
Trial: NCT00359164
Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab
RxNorm normalized name: Verteporfin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds \[light dose of 25 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
Trial: NCT00359164
Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab
RxNorm normalized name: Verteporfin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
Trial: NCT00359164
Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
RxNorm normalized name: Verteporfin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds \[light dose of 12.5 J/cm2\]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham.
Trial: NCT04170309
Drug: Ceftobiprole medocaril
RxNorm normalized name: Ceftobiprole medocaril
DrugBank: Ceftobiprole medocaril (DB14733)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in whom treatment with Ceftobiprole medocaril has been completed
Trial: NCT03210246
Drug: Vilaprisan (BAY 1002670)
RxNorm normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
Trial: NCT03210246
Drug: Vilaprisan Placebo
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
Trial: NCT03044171
Drug: 1.1% Sodium Fluoride
RxNorm normalized name: Neutral 1.1% Sodium Fluoride Dental Gel
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
Trial: NCT03806777
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Highly selective alpha-2 adrenergic agonist with sedative properties.
Trial: NCT03869190
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
Trial: NCT03869190
Drug: Magrolimab (Hu5F9-G4)
RxNorm normalized name: human-bovine reassortant rotavirus strain G4 vaccine
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
Trial: NCT03869190
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21-day cycle.
Trial: NCT03869190
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sacituzumab Govitecan will be administered at a dose of 10 mg/kg by IV on Day 1 and 8 of each 21-day cycle.
Trial: NCT03869190
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
Trial: NCT03869190
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered at a dose of 70mg/m\^2 by IV on Day 1 of each cycle for Cycles 1-3 pre-surgery.
Trial: NCT01221376
Drug: Imatinib Mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
Trial: NCT05210738
Drug: Bulkamid bulking agent
RxNorm normalized name: BULKAMID
DrugBank: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide) (DB14771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral bulking by Bulkamid is used to treat occult SUI
Trial: NCT00171821
Drug: Deferasirox
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03869190
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered at a dose of 1000mg/m\^2 by IV on Days 1 and 8 of each cycle for Cycles 1-3 pre-surgery.
Trial: NCT04596631
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral semaglutide treatment for 52 weeks. All participants will be dose-escalated to an individual maximum tolerated dose.
Trial: NCT00519142
Drug: placebo for mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: three times a day with meals
Trial: NCT00519142
Drug: mitiglinide
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: three times a day with meals
Trial: NCT00519142
Drug: mitiglinide
RxNorm normalized name: mitiglinide
DrugBank: Mitiglinide (DB01252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: two times a day with meals
Trial: NCT00462852
Drug: dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00462852
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04062890
Drug: Vigabatrin Pill
RxNorm normalized name: vigabatrin Pill
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Vigabatrin Pill